Given the shared pathways of neurodegeneration, including the role of ROS and the impairment of the NRF2 pathway, it is plausible that the therapeutic effects observed in PD could extend not only to AD but also to other brain disorders. The gene discussed is NFE2L2; the disease is Alzheimer disease.